KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Esperion Therapeutics filings provide 4 years of Other Non-Current Assets readings, the most recent being $50.0 million for Q3 2022.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $50.0 million in Q3 2022 year-over-year; TTM through Sep 2022 was $50.0 million, a 0.0% change, with the full-year FY2021 number at $50.0 million, changed N/A from a year prior.
  • Other Non-Current Assets hit $50.0 million in Q3 2022 for Esperion Therapeutics, roughly flat from $50.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $50.0 million in Q3 2021 to a low of $928000.0 in Q2 2019.
  • Median Other Non-Current Assets over the past 4 years was $1.3 million (2020), compared with a mean of $23.3 million.
  • The widest YoY moves for Other Non-Current Assets: up 39.44% in 2020, down 22.21% in 2020.
  • Esperion Therapeutics' Other Non-Current Assets stood at $928000.0 in 2019, then soared by 39.44% to $1.3 million in 2020, then surged by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
  • The last three reported values for Other Non-Current Assets were $50.0 million (Q3 2022), $50.0 million (Q2 2022), and $50.0 million (Q1 2022) per Business Quant data.